Zydus has entered into a partnership with Agenus to bring next-generation immunotherapy platform, BOT and BAL, to India. This innovative therapy aims to boost and maintain the immune system’s ability to target tumour cells effectively. The collaboration between Zydus and Agenus signifies a significant step towards advancing cancer treatment options in the region, offering hope to patients seeking advanced therapies for better outcomes in their fight against cancer.
With the licensing of BOT and BAL combination therapies, Zydus is poised to revolutionize the landscape of cancer treatment in India, providing patients with access to cutting-edge immunotherapy options. This partnership highlights the growing importance of immunotherapy in the fight against cancer and underscores the commitment of both companies to advancing oncology research and development. As late-stage CDMO solutions continue to gain traction in the pharmaceutical industry, Zydus’s collaboration with Agenus positions them at the forefront of innovation, paving the way for potentially game-changing advancements in cancer care.
Read more from business-standard.com
